Condition: Endocrine Disease · Sponsor: University Hospital, Bordeaux
The recent development of quantitative steroid metabolome profiling could be of interest for the positive diagnosis of mild autonomous cortisol-secreting adenoma (MACS). The aim of the study is to develop a predictive model of MACS status or non-secreting adenoma (NSA) based on a panel of 19 serum steroids and three clinico-biological parameters (body mass index or BMI, fasting glycaemia, blood pressure) and to estimate its performance for the diagnosis of MACS in a cohort of patients followed in the endocrinology department of Bordeaux University Hospital.
This description comes directly from the study's public registry record.
Amandine FERRIERE · 05 57 57 64 24 · amandine.ferriere@chu-bordeaux.fr
Julie Brossaud · 05.57.82.15.01 · julie.brossaud@chu-bordeaux.fr
Always discuss trial participation with your own doctor first.
| Hôpital du Haut-Lévêque | Pessac, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07352527